Table 3.

CSF biomarkers of CDR‐SB and MMSE change are shown for both cohorts at specified time points, after adjustment for age, sex, APOE status and education.

Time	CDR‐SB change			MMSE change
	Factor	Estimate (95% CI)	P‐value	Factor	Estimate (95% CI)	P‐value
Discovery cohort
9 months	CCL2	1.23 (0.24, 2.22)	0.016	AAT	1.50 (−0.85, 3.85)	0.20
	MMP3	−0.97 (−1.64, −0.29)	0.006	CCL2	−1.54 (−4.09, 1.02)	0.23
				MMP3	2.05 (0.32, 3.78)	0.022
15 months	FGA	−0.27 (−0.73, 0.20)	0.25	AAT	1.53 (−1.24, 4.30)	0.27
	CCL2	2.82 (1.30, 4.34)	<0.001	CCL2	−2.36 (−5.47, 0.76)	0.13
	MMP3	−0.94 (−1.82, −0.05)	0.039	CCL4	1.48 (−0.15, 3.12)	0.073
ADNI Cohort
12 months	AAT	0.37 (−0.10, 0.85)	0.12	CCL2	−1.45 (−2.54, −0.36)	0.009
	CCL4	0.30 (−0.03, 0.63)	0.071	FGA	0.49 (0.13, 0.86)	0.008
	FGA	−0.23 (−0.40, −0.05)	0.011
24 months	CCL2	0.86 (−0.04, 1.75)	0.062	CCL2	−1.46 (−3.19, 0.26)	0.096
	CCL5	0.41 (0.02, 0.79)	0.041	CCL5	−0.43 (−1.18, 0.31)	0.25
				CRP	−0.26 (−0.65, 0.13)	0.20
36 Months	CCL2	1.43 (0.13, 2.73)	0.031	CCL2	−2.87 (−5.16, −0.58)	0.015
	CCL4	0.76 (0.01, 1.52)	0.047	CCL4	−1.36 (−2.71, −0.00)	0.050
	MMP3	−0.53 (−1.25, 0.19)	0.15	CCL5	0.74 (−0.50, 1.98)	0.24

P‐value < 0.05 is noted in bold